These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 25487913)

  • 1. Hemodynamic changes in Alzheimer's disease: A leading role behind the courtain? Commentary on "CSF Aβ1-42 combined with neuroimaging biomarkers in the early detection, diagnosis and prediction of Alzheimer's disease" by Lista et al.
    Diomedi M; Stefani A
    Alzheimers Dement; 2015 Sep; 11(9):1123-4. PubMed ID: 25487913
    [No Abstract]   [Full Text] [Related]  

  • 2. CSF Aβ1-42 combined with neuroimaging biomarkers in the early detection, diagnosis and prediction of Alzheimer's disease.
    Lista S; Garaci FG; Ewers M; Teipel S; Zetterberg H; Blennow K; Hampel H
    Alzheimers Dement; 2014 May; 10(3):381-92. PubMed ID: 23850330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amyloid-β 42/40 cerebrospinal fluid concentration ratio in the diagnostics of Alzheimer's disease: validation of two novel assays.
    Lewczuk P; Lelental N; Spitzer P; Maler JM; Kornhuber J
    J Alzheimers Dis; 2015; 43(1):183-91. PubMed ID: 25079805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Isobaric Quantification of Cerebrospinal Fluid Amyloid-β Peptides in Alzheimer's Disease: C-Terminal Truncation Relates to Early Measures of Neurodegeneration.
    Rogeberg M; Almdahl IS; Wettergreen M; Nilsson LN; Fladby T
    J Proteome Res; 2015 Nov; 14(11):4834-43. PubMed ID: 26452689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NIA-AA staging of preclinical Alzheimer disease: discordance and concordance of CSF and imaging biomarkers.
    Vos SJB; Gordon BA; Su Y; Visser PJ; Holtzman DM; Morris JC; Fagan AM; Benzinger TLS
    Neurobiol Aging; 2016 Aug; 44():1-8. PubMed ID: 27318129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Biomarkers for Alzheimer's disease: after Alzheimer's disease neuroimaging initiative studies].
    Shoji M
    Brain Nerve; 2012 May; 64(5):497-504. PubMed ID: 22570063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The clinical use of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative.
    Molinuevo JL; Blennow K; Dubois B; Engelborghs S; Lewczuk P; Perret-Liaudet A; Teunissen CE; Parnetti L
    Alzheimers Dement; 2014 Nov; 10(6):808-17. PubMed ID: 25150736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reference measurement procedure for CSF amyloid beta (Aβ)
    Pannee J; Portelius E; Minthon L; Gobom J; Andreasson U; Zetterberg H; Hansson O; Blennow K
    J Neurochem; 2016 Nov; 139(4):651-658. PubMed ID: 27579672
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of amyloid β1-42 and neuroimaging biomarkers in Alzheimer's disease.
    Lista S; Emanuele E
    Biomark Med; 2011 Aug; 5(4):411-3. PubMed ID: 21861661
    [No Abstract]   [Full Text] [Related]  

  • 10. Biomarkers in the Diagnosis and Prognosis of Alzheimer's Disease.
    Schaffer C; Sarad N; DeCrumpe A; Goswami D; Herrmann S; Morales J; Patel P; Osborne J
    J Lab Autom; 2015 Oct; 20(5):589-600. PubMed ID: 25424384
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cerebrospinal fluid biomarkers for diagnosis of Alzheimer's disease: beta-amyloid(1-42), tau, phospho-tau-181 and total protein.
    Marksteiner J; Hinterhuber H; Humpel C
    Drugs Today (Barc); 2007 Jun; 43(6):423-31. PubMed ID: 17612711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Cerebrospinal Fluid Aβ1-42/Aβ1-40 Ratio Improves Concordance with Amyloid-PET for Diagnosing Alzheimer's Disease in a Clinical Setting.
    Niemantsverdriet E; Ottoy J; Somers C; De Roeck E; Struyfs H; Soetewey F; Verhaeghe J; Van den Bossche T; Van Mossevelde S; Goeman J; De Deyn PP; Mariën P; Versijpt J; Sleegers K; Van Broeckhoven C; Wyffels L; Albert A; Ceyssens S; Stroobants S; Staelens S; Bjerke M; Engelborghs S
    J Alzheimers Dis; 2017; 60(2):561-576. PubMed ID: 28869470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Varying strength of cognitive markers and biomarkers to predict conversion and cognitive decline in an early-stage-enriched mild cognitive impairment sample.
    Egli SC; Hirni DI; Taylor KI; Berres M; Regeniter A; Gass A; Monsch AU; Sollberger M
    J Alzheimers Dis; 2015; 44(2):625-33. PubMed ID: 25322924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Critical Comparison of Different Biomarkers for Alzheimer's Disease in a Clinical Setting.
    Weise D; Tiepolt S; Awissus C; Hoffmann KT; Lobsien D; Kaiser T; Barthel H; Sabri O; Gertz HJ
    J Alzheimers Dis; 2015; 48(2):425-32. PubMed ID: 26402006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonlinear Association Between Cerebrospinal Fluid and Florbetapir F-18 β-Amyloid Measures Across the Spectrum of Alzheimer Disease.
    Toledo JB; Bjerke M; Da X; Landau SM; Foster NL; Jagust W; Jack C; Weiner M; Davatzikos C; Shaw LM; Trojanowski JQ;
    JAMA Neurol; 2015 May; 72(5):571-81. PubMed ID: 25822737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cognition, brain atrophy, and cerebrospinal fluid biomarkers changes from preclinical to dementia stage of Alzheimer's disease and the influence of apolipoprotein e.
    Susanto TA; Pua EP; Zhou J;
    J Alzheimers Dis; 2015; 45(1):253-68. PubMed ID: 25524955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CSF biomarkers for the differential diagnosis of Alzheimer's disease: A large-scale international multicenter study.
    Ewers M; Mattsson N; Minthon L; Molinuevo JL; Antonell A; Popp J; Jessen F; Herukka SK; Soininen H; Maetzler W; Leyhe T; Bürger K; Taniguchi M; Urakami K; Lista S; Dubois B; Blennow K; Hampel H
    Alzheimers Dement; 2015 Nov; 11(11):1306-15. PubMed ID: 25804998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aminoterminally truncated and oxidized amyloid-β peptides in the cerebrospinal fluid of Alzheimer's disease patients.
    Bibl M; Gallus M; Welge V; Esselmann H; Wiltfang J
    J Alzheimers Dis; 2012; 29(4):809-16. PubMed ID: 22460324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biomarkers for Alzheimer's disease. The research advances incrementally, but clinical use is still years away.
    Harv Ment Health Lett; 2010 Nov; 27(5):1-3. PubMed ID: 21218612
    [No Abstract]   [Full Text] [Related]  

  • 20. CSF Aβ
    Rizzi L; Maria Portal M; Batista CEA; Missiaggia L; Roriz-Cruz M
    Brain Res; 2018 Jan; 1678():27-31. PubMed ID: 29017912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.